Drug intelligence / Profile preview

VETIGEL

Development stage: Unknown
Lead developer: Cresilon
Administration: Topical

Overview

VETIGEL is a plant-based hemostatic gel developed by Cresilon (formerly Suneris) and licensed to Zomedica for the veterinary market. The product is composed of plant-derived polymers, specifically a proprietary algae-based technology, that forms a mechanical barrier to stop bleeding instantly upon application. Unlike traditional hemostatic agents that may require manual pressure or specific environmental conditions, VETIGEL works by interacting with the blood to create a mesh-like seal that facilitates rapid clot formation. It is primarily utilized in veterinary medicine for a wide range of applications, including routine surgeries, dental extractions, liver biopsies, and emergency trauma care, providing a fast and effective solution for hemorrhage control in animals.

Brand names: VETIGEL
Other names: VetiGel

Beyond the preview

Go deeper on VETIGEL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VETIGEL.

Explore the full profile